540702 Stock Overview
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Lasa Supergenerics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹25.53 |
| 52 Week High | ₹40.95 |
| 52 Week Low | ₹20.10 |
| Beta | 0.51 |
| 1 Month Change | 17.11% |
| 3 Month Change | -21.18% |
| 1 Year Change | 2.57% |
| 3 Year Change | -67.29% |
| 5 Year Change | 3.57% |
| Change since IPO | -82.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540702 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.0% | -0.1% | 1.8% |
| 1Y | 2.6% | 55.9% | 46.4% |
Return vs Industry: 540702 underperformed the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: 540702 underperformed the Indian Market which returned 46.4% over the past year.
Price Volatility
| 540702 volatility | |
|---|---|
| 540702 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 540702's share price has been volatile over the past 3 months.
Volatility Over Time: 540702's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 89 | Omkar Herlekar | lasalabs.com |
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide.
Lasa Supergenerics Limited Fundamentals Summary
| 540702 fundamental statistics | |
|---|---|
| Market cap | ₹1.29b |
| Earnings (TTM) | -₹214.42m |
| Revenue (TTM) | ₹1.17b |
1.1x
P/S Ratio-6.0x
P/E RatioIs 540702 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540702 income statement (TTM) | |
|---|---|
| Revenue | ₹1.17b |
| Cost of Revenue | ₹835.05m |
| Gross Profit | ₹333.37m |
| Other Expenses | ₹547.79m |
| Earnings | -₹214.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.28 |
| Gross Margin | 28.53% |
| Net Profit Margin | -18.35% |
| Debt/Equity Ratio | 20.3% |
How did 540702 perform over the long term?
See historical performance and comparison